Compare Charles River Laboratories Intl. Inc (CRL) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Innodata Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.4 (market cap $11.14B), while Innodata Inc trades at $67.78 (market cap $2.19B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.1× Innodata Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| CRL | INOD | |
|---|---|---|
Market Cap | $11.14B | $2.19B |
Sector | Health | Technology |
52-Week High | $233.60 | $121.50 |
52-Week Low | $145.57 | $34.45 |
Enterprise Value | $14.00B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
INOD trades at $68.12, up 0.47% today but down 33% over the past month. The stock shows strong fundamentals with revenue growth to $252M in 2025 and net income of $32M, while beating EPS estimates in recent quarters. Technical indicators signal a bearish trend, with resistance at $69 and support at $67. Recent news highlights AI-driven growth and a new CFO appointment.
Outlook remains positive due to AI demand and raised guidance, but high valuation (P/E 59.89) and customer concentration pose risks. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
